SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

SG Americas Securities LLC raised its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 188.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 60,202 shares of the company’s stock after buying an additional 39,335 shares during the period. SG Americas Securities LLC’s holdings in Xeris Biopharma were worth $172,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its position in Xeris Biopharma by 10.1% in the second quarter. The Manufacturers Life Insurance Company now owns 57,805 shares of the company’s stock worth $130,000 after purchasing an additional 5,291 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Xeris Biopharma by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock worth $278,000 after acquiring an additional 10,632 shares during the period. Simplicity Wealth LLC bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at $27,000. Rhumbline Advisers raised its holdings in Xeris Biopharma by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 189,970 shares of the company’s stock worth $427,000 after purchasing an additional 12,332 shares during the period. Finally, Asset Management Group Inc. grew its holdings in Xeris Biopharma by 130.7% during the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after purchasing an additional 15,000 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Stock Performance

XERS opened at $3.11 on Thursday. The stock has a market cap of $461.08 million, a price-to-earnings ratio of -6.43 and a beta of 2.76. The firm’s fifty day moving average is $2.84 and its 200 day moving average is $2.37. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.46 and a fifty-two week high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same quarter in the prior year, the company posted ($0.14) earnings per share. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Xeris Biopharma in a research note on Thursday, August 15th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.